Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value [Yahoo! Finance]
Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.theravance.com/investor-relations
Company Research
Source: Yahoo! Finance
YUPELRI ® (revefenacin) net sales of $62.2 million , recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 2024 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million , as reported by GSK: Q4 sales of at least ~$260 million needed to earn $25 million milestone Q4 sales of at least ~$610 million needed to earn $50 million milestone Board of Directors announces initiatives to unlock shareholder value and enhance corporate governance DUBLIN Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 and announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value. Reflecting on the quarter's operational performance, Rick Winningham , Theravance Biopharma CEO commented, "Through our collaboration with V
Show less
Read more
Impact Snapshot
Event Time:
TBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBPH alerts
High impacting Theravance Biopharma, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TBPH
News
- KBR Stock Soars 5%: Activist Investor Pushes for Breakup to Unlock 50% Value Surge [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferencePR Newswire
- The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Theravance Biopharma to Participate in an Upcoming Investor ConferencePR Newswire
- Kevin Krause named President and CEO of ArrePath [Yahoo! Finance]Yahoo! Finance
TBPH
Earnings
- 11/12/24 - Miss
TBPH
Sec Filings
- 11/22/24 - Form 4
- 11/22/24 - Form 4
- 11/22/24 - Form 4
- TBPH's page on the SEC website